|
FDA Warns of Possible Bladder Cancer Risk With Takeda Diabetes Drug Actos
The FDA is revising the label of Takeda’s blockbuster Type 2 diabetes drug Actos to warn of a possible increased risk of bladder cancer with long-term use — a move that comes as the drug’s exclusivity is set to end later this summer.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives